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From time to time we need to remind ourselves that
atherosclerosis begins in childhood as fatty streaks. These
lesions are of course benign in that they are asymptomatic,
do not obstruct blood flow, and do not predispose to
thrombosis. However, they are actually anything but be-
nign. They are the precursors of the advanced lesions that
ultimately—decades later—will precipitate coronary throm-
bosis and myocardial infarction (1,2). Fatty streak lesions
and even some fibrous plaques are already well established in
young adulthood. Their anatomic locations in the arterial
tree are very much the same as those of the later
See page 2631
lesions (1,3). Moreover, the risk factors that correlate with
the extent of such early lesions are the same risk factors that
correlate with myocardial infarction later in life (2,4,5). In
other words, the disease does not somehow morph into
another form as we get older; the disease progresses, and the
lesions get larger and become life-threatening. Based on
these insights into the natural history of atherogenesis,
pathologists began urging many years ago that preventive
measures should be instituted earlier in life (6). However,
the drugs available at the time were less than ideal, and there
was no way to directly assess the value of early intervention
and make a meaningful risk/benefit assessment, so the issue
was moot. Today, thanks to advances in our understanding
of the mechanisms regulating blood cholesterol levels and
the genes involved in that regulation, it has become clear
that earlier intervention could improve in a major way the
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The newer genetic evidence. The work by Cohen et al. (7)
n the PCSK9 gene represented a breakthrough in this area.
he PCSK9 gene plays a key role in the regulation of the
ow-density lipoprotein (LDL) receptor, suppressing the
xpression of the receptor and thus increasing LDL levels.
utations causing overexpression of PCSK9 can increase
DL to levels as high as those found in familial hypercho-
esterolemia (8). Conversely, nonsense mutations in the
CSK9 gene allow increased expression of the receptor, thus
owering plasma LDL levels. What Cohen et al. discovered
s that individuals with a particular nonsense mutation in
CSK9 had an LDL level 28% lower than that in the rest of
he population under study. The astonishing finding was
hat the CHD risk in these individuals was reduced by
80%! By comparison, the same 28% decrease in LDL in
he statin trials has only reduced CHD risk by 25% to 35%.
ohen et al. proposed that the much greater effect was due
o the fact that LDL levels in people with PCSK9 loss of
unction mutations were lower right from birth, not just for
he 5 or 6 years of a statin trial, a trial that usually started in
iddle age. Their findings have been amply confirmed
9,10).
In this issue of the Journal, Ference et al. (11) have
rovided a meta-analysis of published data that points up
he magnitude of protection potentially offered by a lifetime
owering of LDL cholesterol (LDL-C). The authors con-
lude that lifetime exposure to an LDL level lowered by
40 mg/dl because of mutations in 1 or more of these
lleles could reduce CHD risk by almost 55%! Ference et al.
11) used Mendelian randomization to examine the impact
f gene polymorphisms affecting LDL levels and CHD risk.
hey included PCSK9 and data on 5 additional genes
elated to cholesterol or lipoprotein metabolism. The data
n PCSK9 are the most striking, but the data on the other
lleles studied, although less impressive, are consonant. If
here are no hidden problems with the methodology; these
ata also suggest that the magnitude of the benefit conferred
y the mutations studied relates directly to the extent that
hey lower plasma LDL no matter what the mechanism by
hich they do so. These alleles all have functions relating to
ipid and lipoprotein metabolism, although the precise
echanisms leading to the low LDL are not known in all
ases. At any rate, the mutations studied are unlikely to be
nfluencing atherogenesis in ways unrelated to lipoprotein
etabolism. Thus, lowering LDL earlier in life, using diet
nd/or drug approaches, could prevent not just 30% of
vents, as in the statin trials, but possibly more like 60%.
A growing body of literature has provided the rationale
or earlier intervention (12–16), not only with respect to
ypercholesterolemia but also with respect to other risk
actors such as hypertension, obesity, and diabetes. Here we
onfine our discussion to hypercholesterolemia. There is
ood reason to predict a very favorable risk/benefit ratio for
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treatment—whether dietary or pharmacological—should
start much sooner than is the practice today (17–19). There
are understandable concerns about treating younger people
and treating them for a lifetime. However, the bulk of
evidence suggests that the benefits will easily outweigh the
risks (12,20–22). The meta-analysis presented by Ference et
al. (11) adds strength to the case. Still, there is understand-
able hesitation to proceed without explicit randomized,
controlled trial (RCT) evidence.
What are the options available? First, we could, as pro-
posed by Domanski et al. (15), undertake a 10-year RCT in
a younger age group (30 to 50 years). To give a clear-cut
result, a sizable investment of time and money would be
required. At least 15 years would be needed overall for
organization, implementation, and interpretation of the
results. Because absolute risk at baseline would be low, risk
reduction might turn out to be limited to those at highest
risk at baseline, making generalization problematic. None-
theless, a trial of this type, even if inconclusive with respect
to major endpoints, could yield valuable information. For
example, it could document the safety and tolerability of
statins with long-term use. It could demonstrate the will-
ingness of younger, asymptomatic individuals to adhere to
statin therapy for many years. A positive result would, of
course, represent a milestone, and a major revision of
guidelines would follow. However, a negative result could
have a chilling effect on further attempts to document the
value of early intervention.
Alternatively, an even more expensive trial design but one
more likely to yield a conclusive result could be considered.
Study subjects would be younger (e.g., 30 to 35 years), have
no existing CHD, have an LDL level 130 mg/dl, and no
more than 2 additional risk factors. Detailed entrance
criteria would have to be carefully chosen in relation to the
study power wanted and the number of subjects that would
yield enough hard endpoints in 20 to 30 years. The aim
would be to select a study population typical for the age
group but not at very high risk. Undoubtedly, this would
cost more and last longer, but in view of the high stakes
involved, it might be the wisest way to go.
A second option would be to take the position that the
evidence already in hand is strong enough to justify chang-
ing the guidelines without waiting for an RCT (16).
Heretical as that may sound, it is by no means unprece-
dented. For example, we already treat children with familial
hypercholesterolemia with drugs as early as age 8 even
though there are no explicit RCT data to justify that
intervention (13). Also, we do not hesitate to recommend
against smoking even though there are no RCT data to back
up that recommendation and there never will be. The
acceptability of this option depends on the strength of our
conviction that the totality of evidence, discussed here and
in other recent papers (23,24), justifies acting without
waiting for the results of a RCT.Interim approaches. Even if one or another type of con-
trolled intervention trial is undertaken, it will be many years
before the results can become available. In the interim, there
are other options to consider.
The first would be to replace the current use of the
10-year Framingham risk score with a lifetime risk score, as
proposed by Lloyd-Jones et al. (13,14). The 10-year Fra-
mingham risk score heavily weights age as a factor. Inter-
vention is not recommended in subjects in their 30s or 40s,
even though their lifetime risk may be very high. In other
words, they may get through the next 10 years without an
event, but their risk factor profile predicts that the chance
that they will eventually, perhaps in their 50s or 60s, have an
event is nevertheless high. A shift to the use of lifetime risk
would result in significantly earlier intervention.
A second approach would be to rethink our criteria for
what represents an acceptable LDL level and set goals that
should be reached at an early age. The 50th percentile for
LDL-C in American adults older than 35 years of age is
130 mg/dl, and the 75th percentile is 160 mg/dl for
men and somewhat lower in women. If the goal for LDL-C
for all adults, not just those with clinical atherosclerotic
isease or diabetes, were set at 100 mg/dl, the majority of
eople could achieve that goal by lifestyle alone. If not, they
ould opt to take a low dose of a cholesterol-lowering drug.
or example, 10 mg of simvastatin will lower LDL-C levels
n average by 30%, and if combined with lifestyle change,
y 40%. This strategy would get at least three fourths of
he population to an LDL-C level of 100 mg/dl. Those
ith higher baseline LDL-C might require a higher dose of
tatin, but drug treatment for anyone with a baseline
DL-C of 160 mg/dl is not difficult to justify.
A final option is to be conservative and stay with
uidelines similar to those currently in place. National
uidelines invariably tend to gravitate toward the conserva-
ive position, which for hypercholesterolemia is to intervene
ater in life. We reject this as an option. The evidence that
arlier intervention will significantly reduce the toll of CHD
s too strong to be ignored. The public and the profession
eed to become aware of the potential benefit of keeping
holesterol low, not just after age 50 or 60 but, even in those
t intermediate risk, beginning at age 30 or 35. To the
idely accepted dictum “the lower the better,” we should
robably add “the earlier the better.”
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